The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.50
Bid: 0.40
Ask: 0.60
Change: 0.00 (0.00%)
Spread: 0.20 (50.00%)
Open: 0.50
High: 0.50
Low: 0.50
Prev. Close: 0.50
SUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

5 Dec 2023 07:00

RNS Number : 6219V
Surgical Innovations Group PLC
05 December 2023
 

Surgical Innovations Group Plc

 ("Surgical Innovations", the "Company" or the "Group")

 

 

Directorate Change

 

Surgical Innovations appoints Keyvan Djamarani as Independent Non-executive Director

Nigel Rogers steps down, concluding the Board succession plan

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces that Keyvan Djamarani has been appointed as Independent Non-executive Director with immediate effect. This follows an extensive process led by an independent head-hunter. At the same time Nigel Rogers, who previously served time as Chair of the Company, will step down from the Board.

 

Keyvan has over 30 years' relevant experience, holding numerous leadership roles in product development within manufacturing organisations covering medical and pharmaceutical drug delivery devices. He has a track record of delivering increased sales, profitability and business critical programmes and projects. Most recently he spent over nine years as Managing Director/Business President at Bespak Europe, a medical and pharmaceutical drug delivery devices business. Keyvan began his career at Unilever working in their Detergents and Personal Products Divisions prior to joining Bespak. At Bespak, Keyvan held several roles across their European and North American divisions. Within this period, from 2002 to 2005, Keyvan was General Manager and President of Bespak Inc. and from 2010 to 2013, Keyvan became CEO of King Systems, an airways management business, encompassing design, development and manufacture of airway management products. Keyvan was most recently a Non-executive Director of CEME Ltd, a not-for-profit business enterprise operating on a 19-acre campus, home to over 100 engineering, technology and training businesses - a role he held for over 16 years.

 

As announced on 22 May 2023, Nigel Rogers will step down from the Board with immediate effect, concluding the final part of the planned Board succession process. Nigel joined the Board in 2015, bringing stability to the Company at a critical time. 

 

Chair of the Company, Jonathan Glenn, commented: "I would like to thank Nigel for the dedicated service he provided to Surgical Innovations over his eight-year tenure, bringing the Company safely through a number of significant challenges including the pandemic. His experience proved invaluable and his insight has always been appreciated by the Board and management.

"I am also delighted to welcome Keyvan to the Board. He has an excellent track record in the medical device sector and brings with him a broad and relevant skillset. His extensive operational experience will provide a wealth of expertise to the Board, affording valuable insight into the challenges of manufacturing as the Company undertakes a major efficiency drive to improve margins."

 

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Dr Keyvan Mehdi Djamarani (aged 62) is currently, or has during the past five years, been a director of the following companies:

 

Current directorships or partnerships

Previous directorships or partnerships

· n/a

· Centre for Engineering and Manufacturing Excellence Ltd

· Bespak Europe Limited

· Integrated Aluminium Components Limited

· The Medical House Group Limited

· The Medical House Limited

· The Medical House Products Limited

· Medical House (ASI) Limited

· Hyperlyser Limited

 

Save as set out in this announcement there are no further details to be disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rule for Companies.

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, CFO

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Oliver Platts

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / 07584 391 303

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUPGUUPUPWGMC
Date   Source Headline
18th Oct 20137:00 amRNSCFO to present at London Investor Show
17th Oct 20137:00 amRNSInternational Clinical Advisory Board Appointment
4th Oct 20137:00 amRNSAppointment to the Clinical Advisory Board
10th Sep 20137:00 amRNSInterim Results
16th Aug 20137:00 amRNSTrading update
19th Jun 20134:06 pmRNSResult of AGM
19th Jun 20132:00 pmRNSAGM Statement
10th Jun 20137:00 amRNSPilot hip arthroscopy test
3rd Jun 20137:00 amRNSAppointment to the Clinical Advisory Board
29th May 20137:00 amRNSNew US dealer
22nd May 20137:00 amRNSDevelopment agreement for Industrial application
8th May 20137:00 amRNSSnr Appointment of President US Sales & Operations
17th Apr 20137:00 amRNSAppointment to the Clinical Advisory Board
9th Apr 20137:00 amRNSPreliminary Results
18th Mar 20137:00 amRNSChange of Adviser
11th Mar 20137:00 amRNSUS appointment to ICAB
19th Feb 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSPretzelFlex 3mm FDA approval
22nd Jan 20137:00 amRNSSecond order of 5mm PretzelFlex® shipped
17th Jan 20137:00 amRNSSI to benefit from £5.05m RGF Grant
10th Jan 20137:00 amRNSDirectors shareholding
18th Dec 20129:24 amRNSDirectors' dealings and issue of equity
18th Dec 20127:00 amRNSAppointments to the Clinical Advisory Board
29th Oct 20127:00 amRNSFirst PretzelFlex® orders shipped to CareFusion
11th Oct 20127:00 amRNSSuccessful exhibition at ISHA in the US
18th Sep 20127:00 amRNSHalf Yearly Report
4th Sep 20127:00 amRNSNotice of Results
30th Aug 20122:14 pmRNSHolding(s) in Company
26th Jun 20127:00 amRNSGrant of options
19th Jun 20123:33 pmRNSResult of AGM
19th Jun 20127:00 amRNSAGM Statement
18th Jun 20127:00 amRNSOEM distribution agreement with CareFusion
31st May 20127:00 amRNSUK distribution agreement
25th May 201211:58 amRNSDirectorate Change
22nd May 20127:00 amRNSPublication of Annual Report and Notice of AGM
1st May 20127:00 amRNSInvestor site visit
24th Apr 20127:00 amRNSFinal Results
20th Apr 20127:00 amRNSNotice of Results
15th Mar 20127:00 amRNSFDA 510(k) approval for reusable PretzelFlexT
23rd Feb 20124:54 pmRNSHolding(s) in Company
17th Feb 20124:36 pmRNSDirector/PDMR Shareholding
14th Feb 20125:49 pmRNSIssue of Equity
1st Feb 20127:00 amRNSRe: US contract and FDA approval
23rd Jan 20127:01 amRNSTrading Statement
2nd Dec 20117:00 amRNSInvestor Site Visit
3rd Nov 20117:00 amRNSIssue of Equity
1st Nov 20117:00 amRNSConfirmation of successful RGF bid
21st Sep 20114:49 pmRNSIssue of Equity
14th Sep 20117:00 amRNSHalf Yearly Report
1st Sep 20115:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.